MedTrace Logo

Perioperative Treatment With Zoledronic Acid in Patients With Resectable Pancreas Cancer

NCT00892242 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2014-09-22

No results posted yet for this study

Summary

The overall purpose of this research is to evaluate the safety and side effects of zoledronic acid (also known as Zometa) in patients before they have surgery to remove the cancer.

Conditions

  • Adenocarcinoma

Interventions

DRUG

Zoledronic acid

Sponsors & Collaborators

  • Washington University School of Medicine

    lead OTHER

Principal Investigators

  • David Linehan, M.D. · Washington University School of Medicine

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-12-31
Primary Completion
2013-04-30
Completion
2013-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00892242 on ClinicalTrials.gov